{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T07:02:27Z","timestamp":1787900547783,"version":"build-2784847793"},"reference-count":70,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,5,6]],"date-time":"2024-05-06T00:00:00Z","timestamp":1714953600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","msard-journal.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Multiple Sclerosis and Related Disorders"],"published-print":{"date-parts":[[2024,7]]},"DOI":"10.1016\/j.msard.2024.105665","type":"journal-article","created":{"date-parts":[[2024,5,6]],"date-time":"2024-05-06T05:20:04Z","timestamp":1714972804000},"page":"105665","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"special_numbering":"C","title":["Clinical outcome analysis of patients with multiple sclerosis \u2013 Analysis from the UK Medical Cannabis Registry"],"prefix":"10.1016","volume":"87","author":[{"given":"Matthew","family":"Murphy","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Varinder","family":"Kaur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanh Lan","family":"Bui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toby","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simon","family":"Erridge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carl","family":"Holvey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ross","family":"Coomber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James J","family":"Rucker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark W","family":"Weatherall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mikael H","family":"Sodergren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.msard.2024.105665_bib0001","doi-asserted-by":"crossref","first-page":"435","DOI":"10.2217\/cer.14.30","article-title":"Impact of Sativex(\u00ae) on quality of life and activities of daily living in patients with multiple sclerosis spasticity","volume":"3","author":"Arroyo","year":"2014","journal-title":"J. Comp. Eff. Res."},{"issue":"6","key":"10.1016\/j.msard.2024.105665_bib0002","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1177\/2045125312457586","article-title":"Cannabis, a complex plant: different compounds and different effects on individuals","volume":"2","author":"Atakan","year":"2012","journal-title":"Ther. Adv. Psychopharmacol."},{"issue":"1","key":"10.1016\/j.msard.2024.105665_bib0003","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1007\/s43441-021-00346-0","article-title":"Real world evidence in medical cannabis research","volume":"56","author":"Banerjee","year":"2022","journal-title":"Ther. Innov. Regul. Sci."},{"issue":"12","key":"10.1016\/j.msard.2024.105665_bib0004","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1016\/S2215-0366(19)30401-8","article-title":"Cannabinoids for the treatment of mental disorders and symptoms of mental disorders: a systematic review and meta-analysis","volume":"6","author":"Black","year":"2019","journal-title":"Lancet Psychiatry"},{"issue":"8","key":"10.1016\/j.msard.2024.105665_bib0005","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1093\/sleep\/33.8.1061","article-title":"Fatigue in multiple sclerosis: mechanisms, evaluation, and treatment","volume":"33","author":"Braley","year":"2010","journal-title":"Sleep."},{"issue":"5","key":"10.1016\/j.msard.2024.105665_bib0006","doi-asserted-by":"crossref","first-page":"401","DOI":"10.3414\/ME17-01-0051","article-title":"The Charlson Comorbidity Index in registry-based research","volume":"56","author":"Brusselaers","year":"2017","journal-title":"Methods Inf. Med."},{"key":"10.1016\/j.msard.2024.105665_bib0007","doi-asserted-by":"crossref","first-page":"n2040","DOI":"10.1136\/bmj.n2040","article-title":"Medical cannabis or cannabinoids for chronic pain: a clinical practice guideline","volume":"374","author":"Busse","year":"2021","journal-title":"BMJ"},{"issue":"1\u20132","key":"10.1016\/j.msard.2024.105665_bib0009","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1615\/CritRevPhysRehabilMed.2013007945","article-title":"A review of spasticity treatments: pharmacological and interventional approaches","volume":"25","author":"Chang","year":"2013","journal-title":"Crit. Rev. Phys. Rehabil. Med."},{"issue":"5","key":"10.1016\/j.msard.2024.105665_bib0008","doi-asserted-by":"crossref","first-page":"553","DOI":"10.5664\/jcsm.4702","article-title":"Sleep disorders in patients with multiple sclerosis","volume":"11","author":"\u010carnick\u00e1","year":"2015","journal-title":"J. Clin. Sleep. Med."},{"key":"10.1016\/j.msard.2024.105665_bib0010","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.neubiorev.2018.07.014","article-title":"Cannabis use and the development of tolerance: a systematic review of human evidence","volume":"93","author":"Colizzi","year":"2018","journal-title":"Neurosci. Biobehav. Rev."},{"issue":"3","key":"10.1016\/j.msard.2024.105665_bib0011","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1111\/j.1468-1331.2006.01639.x","article-title":"Randomized controlled trial of cannabis-based medicine in spasticity caused by multiple sclerosis","volume":"14","author":"Collin","year":"2007","journal-title":"Eur. J. Neurol."},{"issue":"12","key":"10.1016\/j.msard.2024.105665_bib0012","doi-asserted-by":"crossref","first-page":"1678","DOI":"10.1002\/ptr.2806","article-title":"Beneficial effects of a Cannabis sativa extract treatment on diabetes-induced neuropathy and oxidative stress","volume":"23","author":"Comelli","year":"2009","journal-title":"Phytother. Res."},{"issue":"1","key":"10.1016\/j.msard.2024.105665_bib0016","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1186\/s12883-021-02246-0","article-title":"Sativex\u00ae (nabiximols) cannabinoid oromucosal spray in patients with resistant multiple sclerosis spasticity: the Belgian experience","volume":"21","author":"D'Hooghe","year":"2021","journal-title":"BMC Neurol."},{"issue":"10","key":"10.1016\/j.msard.2024.105665_bib0018","doi-asserted-by":"crossref","first-page":"2505","DOI":"10.1038\/sj.npp.1301643","article-title":"Blunted psychotomimetic and amnestic effects of delta-9-tetrahydrocannabinol in frequent users of cannabis","volume":"33","author":"D'Souza","year":"2008","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.msard.2024.105665_bib0013","doi-asserted-by":"crossref","DOI":"10.1016\/j.fitote.2021.104915","article-title":"CBG, CBD, \u03949-THC, CBN, CBGA, CBDA and \u03949-THCA as antioxidant agents and their intervention abilities in antioxidant action","volume":"152","author":"Dawidowicz","year":"2021","journal-title":"Fitoterapia"},{"issue":"3","key":"10.1016\/j.msard.2024.105665_bib0014","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1177\/1756285611403646","article-title":"Symptomatic therapy in multiple sclerosis: a review for a multimodal approach in clinical practice","volume":"4","author":"de Sa","year":"2011","journal-title":"Ther. Adv. Neurol. Disord."},{"key":"10.1016\/j.msard.2024.105665_bib0015","doi-asserted-by":"crossref","first-page":"370","DOI":"10.3389\/fphar.2016.00370","article-title":"A personal retrospective: Elevating Anandamide (AEA) by targeting Fatty Acid Amide Hydrolase (FAAH) and the Fatty Acid Binding Proteins (FABPs)","volume":"7","author":"Deutsch","year":"2016","journal-title":"Front. Pharmacol."},{"issue":"4","key":"10.1016\/j.msard.2024.105665_bib0017","doi-asserted-by":"crossref","first-page":"449","DOI":"10.2174\/1570159X18666200720172624","article-title":"Phytocannabinoids: general aspects and pharmacological potential in neurodegenerative diseases","volume":"19","author":"Dos Reis Rosa Franco","year":"2021","journal-title":"Curr. Neuropharmacol."},{"issue":"12","key":"10.1016\/j.msard.2024.105665_bib0019","doi-asserted-by":"crossref","first-page":"1842","DOI":"10.1016\/j.mayocp.2018.09.005","article-title":"Medical cannabis","volume":"93","author":"Ebbert","year":"2018","journal-title":"Mayo Clin. Proc."},{"key":"10.1016\/j.msard.2024.105665_bib0020","unstructured":"England P.H. Multiple sclerosis: prevalence, incidence and smoking status - data briefing United Kingdom: GOV.UK; 2020 [Available from: https:\/\/www.gov.uk\/government\/publications\/multiple-sclerosis-prevalence-incidence-and-smoking-status\/multiple-sclerosis-prevalence-incidence-and-smoking-status-data-briefing#:~:text=Conclusions,-The%20purpose%20of&text=The%20estimate%20for%20the%20prevalence,cases%20per%20100%2C000%20population%20respectively."},{"key":"10.1016\/j.msard.2024.105665_bib0021","article-title":"An updated analysis of clinical outcome measures across patients from the UK Medical Cannabis Registry","author":"Ergisi","year":"2022","journal-title":"Cannabis. Cannabinoid. Res."},{"issue":"4","key":"10.1016\/j.msard.2024.105665_bib0022","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1080\/17512433.2022.2020640","article-title":"UK Medical Cannabis Registry: an analysis of clinical outcomes of medicinal cannabis therapy for generalized anxiety disorder","volume":"15","author":"Ergisi","year":"2022","journal-title":"Expert. Rev. Clin. Pharmacol."},{"issue":"3","key":"10.1016\/j.msard.2024.105665_bib0024","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1002\/npr2.12183","article-title":"An initial analysis of the UK Medical Cannabis Registry: outcomes analysis of first 129 patients","volume":"41","author":"Erridge","year":"2021","journal-title":"Neuropsychopharmacol. Rep."},{"issue":"Sup3","key":"10.1016\/j.msard.2024.105665_bib0025","doi-asserted-by":"crossref","first-page":"S28","DOI":"10.12968\/bjnn.2022.18.Sup3.S28","article-title":"Medical cannabis in multiple sclerosis","volume":"18","author":"Erridge","year":"2022","journal-title":"Br. J. Neuroscience Nurs."},{"key":"10.1016\/j.msard.2024.105665_bib0023","doi-asserted-by":"crossref","DOI":"10.1177\/20451253221116240","article-title":"Clinical outcome analysis of patients with autism spectrum disorder: analysis from the UK Medical Cannabis Registry","volume":"12","author":"Erridge","year":"2022","journal-title":"Ther. Adv. Psychopharmacol."},{"issue":"1","key":"10.1016\/j.msard.2024.105665_bib0026","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1038\/s41572-018-0041-4","article-title":"Multiple sclerosis","volume":"4","author":"Filippi","year":"2018","journal-title":"Nat. Rev. Dis. Prim."},{"issue":"5","key":"10.1016\/j.msard.2024.105665_bib0027","article-title":"Cannabis and cannabinoids for symptomatic treatment for people with multiple sclerosis","volume":"5","author":"Filippini","year":"2022","journal-title":"Cochrane Database Syst. Rev."},{"issue":"1","key":"10.1016\/j.msard.2024.105665_bib0028","first-page":"1","article-title":"Multiple sclerosis: pathogenesis, symptoms, diagnoses and cell-based therapy","volume":"19","author":"Ghasemi","year":"2017","journal-title":"Cell J."},{"issue":"5","key":"10.1016\/j.msard.2024.105665_bib0029","doi-asserted-by":"crossref","DOI":"10.3390\/life12050682","article-title":"The efficacy of cannabis on multiple sclerosis-related symptoms","volume":"12","author":"Haddad","year":"2022","journal-title":"Life"},{"issue":"4","key":"10.1016\/j.msard.2024.105665_bib0030","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1080\/17512433.2022.2017771","article-title":"UK Medical Cannabis registry: an analysis of clinical outcomes of medicinal cannabis therapy for chronic pain conditions","volume":"15","author":"Harris","year":"2022","journal-title":"Expert. Rev. Clin. Pharmacol."},{"issue":"2","key":"10.1016\/j.msard.2024.105665_bib0031","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1159\/000095699","article-title":"Symptomatic treatment of multiple sclerosis. Multiple Sclerosis Therapy Consensus Group (MSTCG) of the German Multiple Sclerosis Society","volume":"56","author":"Henze","year":"2006","journal-title":"Eur. Neurol."},{"issue":"10","key":"10.1016\/j.msard.2024.105665_bib0032","doi-asserted-by":"crossref","first-page":"1727","DOI":"10.1007\/s11136-011-9903-x","article-title":"Development and preliminary testing of the new five-level version of EQ-5D (EQ-5D-5L)","volume":"20","author":"Herdman","year":"2011","journal-title":"Qual. Life Res."},{"key":"10.1016\/j.msard.2024.105665_bib0033","series-title":"Multiple Sclerosis: Current Status and Strategies for the Future","first-page":"115","author":"Johnston","year":"2002"},{"issue":"12","key":"10.1016\/j.msard.2024.105665_bib0035","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.1002\/jcph.1961","article-title":"Clinical outcome data of first cohort of chronic pain patients treated with cannabis-based sublingual oils in the United Kingdom: analysis from the UK Medical Cannabis Registry","volume":"61","author":"Kawka","year":"2021","journal-title":"J. Clin. Pharmacol."},{"key":"10.1016\/j.msard.2024.105665_bib0036","first-page":"294","article-title":"Cannabinoid receptors in the central nervous system: their signaling and roles in disease","volume":"10","author":"Kendall","year":"2016","journal-title":"Front. Cell Neurosci."},{"issue":"6","key":"10.1016\/j.msard.2024.105665_bib0037","doi-asserted-by":"crossref","first-page":"5117","DOI":"10.1007\/s11033-022-07223-5","article-title":"Cannabinoid and endocannabinoid system: a promising therapeutic intervention for multiple sclerosis","volume":"49","author":"Khan","year":"2022","journal-title":"Mol. Biol. Rep."},{"issue":"4","key":"10.1016\/j.msard.2024.105665_bib0038","doi-asserted-by":"crossref","DOI":"10.3390\/ijerph19042203","article-title":"Adherence to therapy in patients with multiple sclerosis-review","volume":"19","author":"Ko\u0142tuniuk","year":"2022","journal-title":"Int. J. Environ. Res. Public Health"},{"issue":"4","key":"10.1016\/j.msard.2024.105665_bib0039","doi-asserted-by":"crossref","DOI":"10.1016\/j.jpain.2009.01.258","article-title":"Patient global impression of change scores within the context of a chronic pain rehabilitation program","volume":"10","author":"L Ferguson","year":"2009","journal-title":"J. Pain"},{"issue":"3","key":"10.1016\/j.msard.2024.105665_bib0040","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1097\/MLR.0b013e318160d093","article-title":"Validation and standardization of the Generalized Anxiety Disorder Screener (GAD-7) in the general population","volume":"46","author":"L\u00f6we","year":"2008","journal-title":"Med. Care"},{"key":"10.1016\/j.msard.2024.105665_bib0041","doi-asserted-by":"crossref","first-page":"91","DOI":"10.4103\/sni.sni_45_18","article-title":"Review of the neurological benefits of phytocannabinoids","volume":"9","author":"Maroon","year":"2018","journal-title":"Surg. Neurol. Int."},{"key":"10.1016\/j.msard.2024.105665_bib0034","unstructured":"MHRA, 2020. The supply, manufacture, importation and distribution of unlicensed cannabis-based products for medicinal use in humans \u2018specials\u2019. Available from: https:\/\/assets.publishing.service.gov.uk\/media\/5e58eefb86650c53a363f77c\/Cannabis_Guidance__unlicensed_CBPMs__updated_2020.pdf."},{"key":"10.1016\/j.msard.2024.105665_bib0042","unstructured":"NICE. Cannabis-based medicinal products NICE guideline United Kingdom 2019 [Available from: https:\/\/www.nice.org.uk\/guidance\/ng144\/resources\/cannabisbased-medicinal-products-pdf-66141779817157."},{"key":"10.1016\/j.msard.2024.105665_bib0043","unstructured":"NIDA. Sex and gender differences in substance use 2022 [Available from: https:\/\/nida.nih.gov\/publications\/research-reports\/substance-use-in-women\/sex-gender-differences-in-substance-use."},{"issue":"2","key":"10.1016\/j.msard.2024.105665_bib0044","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1007\/s11910-018-0814-x","article-title":"The use of cannabis and cannabinoids in treating symptoms of multiple sclerosis: a systematic review of reviews","volume":"18","author":"Nielsen","year":"2018","journal-title":"Curr. Neurol. Neurosci. Rep."},{"issue":"2","key":"10.1016\/j.msard.2024.105665_bib0045","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1177\/1352458511419700","article-title":"A placebo-controlled, parallel-group, randomized withdrawal study of subjects with symptoms of spasticity due to multiple sclerosis who are receiving long-term Sativex\u00ae (nabiximols)","volume":"18","author":"Notcutt","year":"2012","journal-title":"Mult. Scler."},{"issue":"9","key":"10.1016\/j.msard.2024.105665_bib0046","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1111\/j.1468-1331.2010.03328.x","article-title":"A randomized, double-blind, placebo-controlled, parallel-group, enriched-design study of nabiximols* (Sativex(\u00ae)), as add-on therapy, in subjects with refractory spasticity caused by multiple sclerosis","volume":"18","author":"Novotna","year":"2011","journal-title":"Eur. J. Neurol."},{"issue":"3","key":"10.1016\/j.msard.2024.105665_bib0047","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1080\/17512433.2023.2183841","article-title":"An observational study of safety and clinical outcome measures across patient groups in the United Kingdom Medical Cannabis Registry","volume":"16","author":"Olsson","year":"2023","journal-title":"Expert. Rev. Clin. Pharmacol."},{"issue":"9","key":"10.1016\/j.msard.2024.105665_bib0049","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1136\/jnnp-2015-312591","article-title":"Efficacy and safety of cannabinoid oromucosal spray for multiple sclerosis spasticity","volume":"87","author":"Patti","year":"2016","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"issue":"9","key":"10.1016\/j.msard.2024.105665_bib0048","doi-asserted-by":"crossref","first-page":"2744","DOI":"10.1111\/ene.15412","article-title":"A real-world evidence study of nabiximols in multiple sclerosis patients with resistant spasticity: analysis in relation to the newly described 'spasticity-plus syndrome'","volume":"29","author":"Patti","year":"2022","journal-title":"Eur. J. Neurol."},{"issue":"12 Suppl","key":"10.1016\/j.msard.2024.105665_bib0050","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1586\/14737175.2013.865877","article-title":"Advances in the management of multiple sclerosis spasticity: experiences from recent studies and everyday clinical practice","volume":"13","author":"Pozzilli","year":"2013","journal-title":"Expert. Rev. Neurother."},{"issue":"1","key":"10.1016\/j.msard.2024.105665_bib0051","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1186\/s13643-019-1243-x","article-title":"Benefits and harms of medical cannabis: a scoping review of systematic reviews","volume":"8","author":"Pratt","year":"2019","journal-title":"Syst. Rev."},{"key":"10.1016\/j.msard.2024.105665_bib0053","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/j.euroneuro.2020.01.006","article-title":"Blunted highs: pharmacodynamic and behavioral models of cannabis tolerance","volume":"36","author":"Ramaekers","year":"2020","journal-title":"Eur. Neuropsychopharmacol."},{"key":"10.1016\/j.msard.2024.105665_bib0052","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/j.euroneuro.2020.01.006","article-title":"Blunted highs: pharmacodynamic and behavioral models of cannabis tolerance","volume":"36","author":"Ramaekers","year":"2020","journal-title":"Eur. Neuropsychopharmacol."},{"issue":"6","key":"10.1016\/j.msard.2024.105665_bib0054","first-page":"28","article-title":"Disease-modifying therapies in multiple sclerosis: overview and treatment considerations","volume":"33","author":"Robertson","year":"2016","journal-title":"Fed. Pract."},{"issue":"5","key":"10.1016\/j.msard.2024.105665_bib0055","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1038\/s41582-019-0170-8","article-title":"Reaching an evidence-based prognosis for personalized treatment of multiple sclerosis","volume":"15","author":"Rotstein","year":"2019","journal-title":"Nat. Rev. Neurol."},{"issue":"1","key":"10.1016\/j.msard.2024.105665_bib0056","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1186\/s12888-019-2409-8","article-title":"Medicinal cannabis for psychiatric disorders: a clinically-focused systematic review","volume":"20","author":"Sarris","year":"2020","journal-title":"BMC Psychiatry"},{"issue":"1","key":"10.1016\/j.msard.2024.105665_bib0057","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1007\/s00415-012-6634-z","article-title":"Sativex long-term use: an open-label trial in patients with spasticity due to multiple sclerosis","volume":"260","author":"Serpell","year":"2013","journal-title":"J. Neurol."},{"issue":"12","key":"10.1016\/j.msard.2024.105665_bib0058","doi-asserted-by":"crossref","first-page":"877","DOI":"10.30773\/pi.2019.0106","article-title":"Neuropsychiatric symptoms of multiple sclerosis: state of the art","volume":"16","author":"Silveira","year":"2019","journal-title":"Psychiatry Investig."},{"issue":"11","key":"10.1016\/j.msard.2024.105665_bib0059","doi-asserted-by":"crossref","first-page":"1849","DOI":"10.5664\/jcsm.7478","article-title":"A new single-item sleep quality scale: results of psychometric evaluation in patients with chronic primary insomnia and depression","volume":"14","author":"Snyder","year":"2018","journal-title":"J. Clin. Sleep. Med."},{"issue":"1","key":"10.1016\/j.msard.2024.105665_bib0060","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1007\/s11910-012-0320-5","article-title":"Pain and multiple sclerosis: pathophysiology and treatment","volume":"13","author":"Solaro","year":"2013","journal-title":"Curr. Neurol. Neurosci. Rep."},{"issue":"10","key":"10.1016\/j.msard.2024.105665_bib0061","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1001\/archinte.166.10.1092","article-title":"A brief measure for assessing generalized anxiety disorder: the GAD-7","volume":"166","author":"Spitzer","year":"2006","journal-title":"Arch. Intern. Med."},{"key":"10.1016\/j.msard.2024.105665_bib0062","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1016\/j.jad.2020.01.032","article-title":"Sensitivity to change and minimal clinically important difference of the 7-item Generalized Anxiety Disorder Questionnaire (GAD-7)","volume":"265","author":"Toussaint","year":"2020","journal-title":"J. Affect. Disord."},{"issue":"3","key":"10.1016\/j.msard.2024.105665_bib0063","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/S1053-4296(03)00031-6","article-title":"CTCAE v3.0: development of a comprehensive grading system for the adverse effects of cancer treatment","volume":"13","author":"Trotti","year":"2003","journal-title":"Semin. Radiat. Oncol."},{"issue":"3","key":"10.1016\/j.msard.2024.105665_bib0064","doi-asserted-by":"crossref","DOI":"10.3390\/medicines5030059","article-title":"Pain modulation after oromucosal cannabinoid spray (SATIVEX(\u00ae)) in patients with multiple sclerosis: a study with quantitative sensory testing and laser-evoked potentials","volume":"5","author":"Turri","year":"2018","journal-title":"Medicines"},{"issue":"5","key":"10.1016\/j.msard.2024.105665_bib0066","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1016\/j.jval.2012.02.008","article-title":"Interim scoring for the EQ-5D-5L: mapping the EQ-5D-5L to EQ-5D-3L value sets","volume":"15","author":"van Hout","year":"2012","journal-title":"Value Health"},{"issue":"4","key":"10.1016\/j.msard.2024.105665_bib0065","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1191\/1352458504ms1048oa","article-title":"Efficacy, safety and tolerability of an orally administered cannabis extract in the treatment of spasticity in patients with multiple sclerosis: a randomized, double-blind, placebo-controlled, crossover study","volume":"10","author":"Vaney","year":"2004","journal-title":"Mult. Scler."},{"issue":"3","key":"10.1016\/j.msard.2024.105665_bib0067","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1007\/BF02260859","article-title":"A health-related quality of life measure for multiple sclerosis","volume":"4","author":"Vickrey","year":"1995","journal-title":"Qual. Life Res."},{"issue":"8","key":"10.1016\/j.msard.2024.105665_bib0068","doi-asserted-by":"crossref","first-page":"573","DOI":"10.7326\/0003-4819-147-8-200710160-00010","article-title":"The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies","volume":"147","author":"von Elm","year":"2007","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/j.msard.2024.105665_bib0069","doi-asserted-by":"crossref","first-page":"n1034","DOI":"10.1136\/bmj.n1034","article-title":"Medical cannabis or cannabinoids for chronic non-cancer and cancer related pain: a systematic review and meta-analysis of randomised clinical trials","volume":"374","author":"Wang","year":"2021","journal-title":"BMJ"},{"issue":"12","key":"10.1016\/j.msard.2024.105665_bib0070","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1212\/WNL.0000000000000250","article-title":"Summary of evidence-based guideline: complementary and alternative medicine in multiple sclerosis: report of the guideline development subcommittee of the American Academy of Neurology","volume":"82","author":"Yadav","year":"2014","journal-title":"Neurology"}],"container-title":["Multiple Sclerosis and Related Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034824002426?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034824002426?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,7,13]],"date-time":"2024-07-13T08:07:02Z","timestamp":1720858022000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2211034824002426"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7]]},"references-count":70,"alternative-id":["S2211034824002426"],"URL":"https:\/\/doi.org\/10.1016\/j.msard.2024.105665","relation":{},"ISSN":["2211-0348"],"issn-type":[{"value":"2211-0348","type":"print"}],"subject":[],"published":{"date-parts":[[2024,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Clinical outcome analysis of patients with multiple sclerosis \u2013 Analysis from the UK Medical Cannabis Registry","name":"articletitle","label":"Article Title"},{"value":"Multiple Sclerosis and Related Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.msard.2024.105665","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"105665"}}